Breast Cancer Research and Treatment

, Volume 103, Issue 3, pp 303–311 | Cite as

Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy

  • Daniel H. S. Silverman
  • Christine J. Dy
  • Steven A. Castellon
  • Jasmine Lai
  • Betty S. Pio
  • Laura Abraham
  • Kari Waddell
  • Laura Petersen
  • Michael E. Phelps
  • Patricia A. Ganz
Clinical Trial


Purpose To explore the relationship of regional cerebral blood flow and metabolism with cognitive function and past exposure to chemotherapy for breast cancer.

Patients and methods Subjects treated for breast cancer with adjuvant chemotherapy remotely (5–10 years previously) were studied with neuropsychologic testing and positron emission tomography (PET), and were compared with control subjects who had never received chemotherapy. [O-15] water PET scans was acquired during performance of control and memory-related tasks to evaluate cognition-related cerebral blood flow, and [F-18] fluorodeoxyglucose (FDG) PET scans were acquired to evaluate resting cerebral metabolism. PET scans were analyzed by statistical parametric mapping and region of interest methods of analysis.

Results During performance of a short-term recall task, modulation of cerebral blood flow in specific regions of frontal cortex and cerebellum was significantly altered in chemotherapy-treated subjects. Cerebral activation in chemotherapy-treated subjects differed most significantly from untreated subjects in inferior frontal gyrus, and resting metabolism in this area correlated with performance on a short-term memory task previously found to be particularly impaired in chemotherapy-treated subjects. In examining drug-class specific effects, metabolism of the basal ganglia was significantly decreased in tamoxifen + chemotherapy-treated patients compared with chemotherapy-only breast cancer subjects or with subjects who had not received chemotherapy, while chemotherapy alone was not associated with decreased basal ganglia activity relative to untreated subjects.

Conclusion Specific alterations in activity of frontal cortex, cerebellum, and basal ganglia in breast cancer survivors were documented by functional neuroimaging 5–10 years after completion of chemotherapy.


Positron emission tomography Brain Breast cancer Tamoxifen Adjuvant chemotherapy FDG Cerebral blood flow 



This research was funded by the Breast Cancer Research Foundation and by an American Cancer Society Clinical Research Professorship award to Dr. Ganz. The authors have no financial interests or relationships with industry which bear on the subject matter described in the paper. We are indebted to Erin Siu for her assistance in manuscript preparation.


  1. 1.
    Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics. CA Cancer J Clin 55:10–30PubMedCrossRefGoogle Scholar
  2. 2.
    Ganz PA (2002) What outcomes matter to patients: a physician-researcher point of view. MedCare 40:III11-III19Google Scholar
  3. 3.
    Phillips KA, Bernhard J (2003) Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 95:190–197PubMedCrossRefGoogle Scholar
  4. 4.
    Ahles TA, Saykin A (2001) Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 19:812–820PubMedCrossRefGoogle Scholar
  5. 5.
    Meyers CA (2000) Neurocognitive dysfunction in cancer patients. Oncology 14:75–79PubMedGoogle Scholar
  6. 6.
    Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla IK, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long- term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493PubMedCrossRefGoogle Scholar
  7. 7.
    Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701PubMedGoogle Scholar
  8. 8.
    Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955–69PubMedCrossRefGoogle Scholar
  9. 9.
    Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640–650PubMedCrossRefGoogle Scholar
  10. 10.
    Tchen N, Juffs HG, Downie FP, Qi-Long Y, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21:4175–4183PubMedCrossRefGoogle Scholar
  11. 11.
    van Dam FS, Schagen SB, Muller MJ, Boogerd W, Wall E, Droogleever Fortuyn ME, Rodenhuis S (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218PubMedCrossRefGoogle Scholar
  12. 12.
    Wieneke MH, ER Dienst (1995) Neuropsychological Assessments of Cognitive Functioning Following Chemotherapy for Breast Cancer. Psycho-Oncology 4:61–66CrossRefGoogle Scholar
  13. 13.
    Wefel JS, Lenzi R, Theriault RL, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299PubMedCrossRefGoogle Scholar
  14. 14.
    Arpels JC (1996) The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. A hypothesis and review of supporting data. J Reprod Med 41:633–639PubMedGoogle Scholar
  15. 15.
    Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S (2004) Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13:61–66PubMedCrossRefGoogle Scholar
  16. 16.
    Paganini-Hill A, Clark LJ (2000) Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64:165–176PubMedCrossRefGoogle Scholar
  17. 17.
    Silverman DHS, Alavi A (2005) PET imaging in the assessment of normal and impaired cognitive function. Radiologic Clin North Am Saunders/Elsevier, Philadelphia, 43:67–77Google Scholar
  18. 18.
    Lai J, Dy CJ, Pio BS, Ganz PA, Castellon SA, Abraham L, Waddell K, Phelps ME, Bookheimer SY, Silverman DHS (2005) Anterior cingulate and temporal lobe regions associated with congruence of memory recall to mood. J Nucl Med 46(5, abstr. suppl):no. 29Google Scholar
  19. 19.
    Rasgon NL, Silverman D, Siddarth P, Miller K, Ercoli LM, Elman S, Lavretsky H, Huang S-C, Phelps PE, Small GW (2005) Estrogen use and brain metabolic change in postmenopausal women with age-associated memory decline. Neurobiology of Aging 226:229–235CrossRefGoogle Scholar
  20. 20.
    Talairach J, Tournoux P (1988) Co-planar stereotaxic atlas of the human brain. 3-dimensional proportional system: An approach to cerebral imaging. New York: ThiemeGoogle Scholar
  21. 21.
    Friston K, Ashburner J, Heather J, et al (2003) Statistical Parametric Mapping (SPM2). Available at (The Wellcome Department of Cognitive Neurology, University College London, London)Google Scholar
  22. 22.
    Partridge AH, Burstein HJ, Winer EP (2001) Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 135–142Google Scholar
  23. 23.
    Ganz PA (2001a) Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst Monogr 130–134Google Scholar
  24. 24.
    Shapiro CL, Recht A (2001) Side Effects of Adjuvant Treatment of Breast Cancer. N Engl J Med 344:1997–2008PubMedCrossRefGoogle Scholar
  25. 25.
    Ganz PA, Hirji K, Sim MS, Schag CA, Fred C, Polinsky ML (1993) Predicting psychosocial risk in patients with breast cancer. Med Care 31:419–431PubMedCrossRefGoogle Scholar
  26. 26.
    Schag CA, Ganz PA, Polinsky ML, Fred C, Hirji K, Petersen L (1993) Characteristics of women at risk for psychosocial distress in the year after breast cancer. J Clin Oncol 11:783–793PubMedGoogle Scholar
  27. 27.
    Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH (1999) Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17:2371–2380PubMedGoogle Scholar
  28. 28.
    Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE (1998a) Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol 16:501–514Google Scholar
  29. 29.
    Rowland JH, Desmond KA, Meyerowitz BE, Belin TR, Wyatt GE, Ganz PA (2000) Role of breast reconstructive surgery in physical and emotional outcomes among breast cancer survivors. J Natl Cancer Inst 92:1422–1429PubMedCrossRefGoogle Scholar
  30. 30.
    Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR (2000) Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743–753PubMedGoogle Scholar
  31. 31.
    Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA (1998b) Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 152:396–411Google Scholar
  32. 32.
    Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR (2000) Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 92:1054–1064PubMedCrossRefGoogle Scholar
  33. 33.
    Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94:39–49PubMedGoogle Scholar
  34. 34.
    Loprinzi CL, Thome SD (2001) Understanding the Utility of Adjuvant Systemic Therapy for Primary Breast Cancer. J Clin Oncol 19:972–979PubMedGoogle Scholar
  35. 35.
    Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer. J Clin Oncol 19:980–991PubMedGoogle Scholar
  36. 36.
    Ganz PA (1998) Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? J Natl Cancer Inst 90:182–183 PubMedCrossRefGoogle Scholar
  37. 37.
    Castellon SA, Silverman DHS, Ganz P (2005) Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Research and Treatment 92:199–206PubMedCrossRefGoogle Scholar
  38. 38.
    Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ (2004) Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage 21:364–371PubMedCrossRefGoogle Scholar
  39. 39.
    Block RI, O’Leary DS, Hichwa RD, Augustinack JC, Ponot LLB, Ghoneim MM, Arndt S, Hurtig RR, Watkins GL, Hall JA, Nathan PE, Andreasen NC (2002) Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 72:237–250PubMedCrossRefGoogle Scholar
  40. 40.
    Schmamann JD, ed: The cerebellum and cognition. Academic Press, San Diego, 1997Google Scholar
  41. 41.
    Silverman DHS and Melega WP (2004) Molecular imaging of biological processes with PET: evaluating biologic bases of cerebral function. In PET: Molecular Imaging and Its Biological Applications ME Phelps, ed., Springer-Verlag, New York, pp. 509–583Google Scholar
  42. 42.
    Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DHS (2005) 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. J Nucl Med 46:1455–1459PubMedGoogle Scholar
  43. 43.
    Ciocca DR, Roig LM (1995) Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr Rev 16:35–62PubMedCrossRefGoogle Scholar
  44. 44.
    Hampson E (1990) Variations in sex-related cognitive abilities across the menstrual cycle. Brain Cogn 14:26–43PubMedCrossRefGoogle Scholar
  45. 45.
    Komenich PKD, Lane M, Dickey RP, Stone SC (1978) Gonadal hormones and cognitive performance. Physiological Psychology 6:115–120Google Scholar
  46. 46.
    Jacobs DM, Tang MX, Stern Y, Sano M, Marder K, Bell KL, Schofield P, Dooneief G, Gurland B, Mayeux R (1998) Cognitive function in nondemented older women who took estrogen after menopause. Neurology 50:368–373PubMedGoogle Scholar
  47. 47.
    McLay RN, Maki PM, Lyketsos CG (2003) Nulliparity and late menopause are associated with decreased cognitive decline. Journal of Neuropsychiatry and Clinical Neurosciences 15:161–167PubMedGoogle Scholar
  48. 48.
    Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD, Metter E (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 48:1517–1521PubMedGoogle Scholar
  49. 49.
    Paganini-Hill A, Henderson VW (1996) Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 156:2213–2217PubMedCrossRefGoogle Scholar
  50. 50.
    Maki PM, Resnick SM (2000) Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiology of Aging 21(2):373–83PubMedCrossRefGoogle Scholar
  51. 51.
    Shaywitz SE, Shaywitz BA, Pugh KR, et al (1999) Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 281:1197–202PubMedCrossRefGoogle Scholar
  52. 52.
    LeBlanc ES, Janowsky J, Chan BK, Nelson HD (2001) Hormone replacement therapy and cognition: systematic review and meta- analysis. JAMA 285:1489–1499PubMedCrossRefGoogle Scholar
  53. 53.
    Haskell SG, Richardson ED, Horwitz RI (1997) The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. J Clin Epidemiol 50:1249–1264PubMedCrossRefGoogle Scholar
  54. 54.
    Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones III BN, Assaf AR, Jackson RD, Morley Kotchen J, Wassertheil-Smoller S, Wactawski-Wende J (2003) Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women’s Health Initiative Memory Study: A Randomized Controlled Trial. JAMA 289:2651PubMedCrossRefGoogle Scholar
  55. 55.
    Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass MLS, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D (2003) Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women: The Women’s Health Initiative Memory Study: A Randomized Controlled Trial. JAMA 289:2663PubMedCrossRefGoogle Scholar
  56. 56.
    Larson SJ, Dunn AJ (2001) Behavioral effects of cytokines. Brain Behav Immun 15:371–387PubMedCrossRefGoogle Scholar
  57. 57.
    Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T (2001) Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58:445–452PubMedCrossRefGoogle Scholar
  58. 58.
    Lerner DM, Stoudemire A, Rosenstein DL (1999) Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 40:428–435PubMedGoogle Scholar
  59. 59.
    Denicoff KD, Rubinow DR, Papa MQ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA (1987) The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107:293–300PubMedGoogle Scholar
  60. 60.
    Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P (1998) Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25:39–47PubMedGoogle Scholar
  61. 61.
    Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ (2001) Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26:797–808PubMedCrossRefGoogle Scholar
  62. 62.
    Singh VK, Guthikonda P (1997) Circulating cytokines in Alzheimer’s disease. J Psychiatr Res 31:657–660PubMedCrossRefGoogle Scholar
  63. 63.
    Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH (2003) Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer’s disease. J Neurol Neurosurg Psychiatry Jun;74(6):788–9Google Scholar
  64. 64.
    Papassotiropoulos A, Bagli M, Jessen F, Bayer RA, Maier W, Rao ML, Heun R (1999) A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer’s disease. Ann Neurol 45:666–668PubMedCrossRefGoogle Scholar
  65. 65.
    Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE (2002) Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 59:371–378PubMedGoogle Scholar
  66. 66.
    Maier SF (2003) Bi-directional immune-brain communication: Implications for understanding stress, pain, and cognition. Brain, Behavior & Immunity 17:69–85CrossRefGoogle Scholar
  67. 67.
    Pugh RC, Fleshner M, Watkins LR, Maier SF, Rudy JW (2001) The immune system and memory consolidation: A role for the cytokine IL-1beta. Neuroscience & Biobehavioral Reviews 25:29–41CrossRefGoogle Scholar
  68. 68.
    Blair JR, Spreen O: Predicting pre-morbid IQ (1989) a revision of the National Adult Reading Test. The Clinical Neuropsychologist, 3:129–136Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Daniel H. S. Silverman
    • 1
    • 5
  • Christine J. Dy
    • 1
  • Steven A. Castellon
    • 2
    • 4
  • Jasmine Lai
    • 1
  • Betty S. Pio
    • 1
  • Laura Abraham
    • 3
  • Kari Waddell
    • 3
  • Laura Petersen
    • 3
  • Michael E. Phelps
    • 1
  • Patricia A. Ganz
    • 3
  1. 1.Department of Molecular and Medical PharmacologyUniversity of California, David Geffen School of MedicineLos AngelesUSA
  2. 2.Department of Psychiatry and Biobehavioral ScienceUniversity of California, David Geffen School of MedicineLos AngelesUSA
  3. 3.Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer CenterUniversity of California, David Geffen School of MedicineLos AngelesUSA
  4. 4.Greater Los Angeles VA Healthcare SystemLos AngelesUSA
  5. 5.Ahmanson Biological Imaging Division, CHS AR-144 UCLA Medical Center, MC694215Los AngelesUSA

Personalised recommendations